The biopharmaceutical market performed well in the first half, up more than 40%

Since the first half of this year, the financial sector and head institutions have accelerated the layout and investment process, and the development prospects of the biopharmaceutical industry are very broadData show that this year's pharmaceutical and biological sector market performance is eye-catching, the first half of the increase of more than 40%, as of July 23, the second half of the year has risen 13.74 percent, significantly surpassing the CSI 300 index, many stocks have even doubled the earningsThe first half of the biopharmaceutical market performance is eye-catching (Photo Source: Pharmaceutical Network) Industry said that If China's pharmaceutical market continues to maintain an annualized growth rate of 8.1%, will achieve 1.79 trillion yuan in 2020With the continuous upgrading of consumption level and the increase of chronic disease syllable diseases under the aging, the market size of China's biologic drug market will gradually increase, and the market size of China's biologic drug market is forecast to reach 833.2 billion yuan in 2025As a strategic emerging industry, the biopharmaceutical industry is embarking on the fast track of industrial development under the impetus of favorable policies such as the reform of the GEM registration systemThe industry said that in order to grasp the strategic opportunities of technological transformation, in the new round of scientific and technological revolution to seize the opportunity, the state through major scientific and technological special projects, key research and development programs, the National Natural Science Foundation and other channels, increase investment in innovation in biotechnologyChina's biotechnology has developed rapidly, and breakthroughs have been made in stem cells, synthetic biology, neurobiology, nanobiology, imaging technology and other fieldsIt is predicted that with the national emphasis on the biopharmaceutical industry, the market size of China's biopharmaceutical industry will return to the growth rate of 10%-15% in the first 1017In addition, the industry believes that according to the "two logic" analysis, the pharmaceutical sector in July and August will continue to strengthenThe pharmaceutical sector as a whole reported better-than-expected second-quarter results, and positive feedback on the earning stake effect of the pharmaceutical sectorIn addition, the domestic macroeconomic environment has undergone subtle changes, the domestic economy within the cycle mainlyThe global innovation and pharmaceutical climate continues to rise, and the epidemic not only has a short-term boost to medical protection, but also has a profound impact on the healthy development of the pharmaceutical industryThese factors will support the long-term bull market in the pharmaceutical industryBased on the future of the optimistic, public funds significantly increased the position of pharmaceutical biologyData show that in the top 20 stocks, the second quarter of this year active funds plus pharmaceutical biology and technology, reduced positions in real estate and financeThe top ten heavy stocks of Chinese medicine biology accounted for three seats, pharmaceutical stocks Hengrui Pharmaceuticals, Changchun Gaoxin, Meirui Medical and Pharmaceutical Mingkang have all been increased positionsAnalysts said, "On this wave of biomedicine, we should look a little further, the future time gradually longer, discount back, can support the current wave of market performance." "In the bio-medicine sector we have been constantly increasing our holdings, almost never exiting ""You can think more about choosing some head business Because this industry in China is only just beginning, the future development space is very large, the head enterprise has obtained a very good resource advantage There is no doubt that in the future development process, they are still very large space, relatively small risk "It is understood that the development of China's entire industry, including the approval of drug certificates, the reform of the evaluation system, access from the perspective of health insurance these systems reform, these major industry reforms further deepened The big background or promote the industry more rapid forward development, more biopharmaceutical companies appear, biopharmaceutical will usher in great development opportunities